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Abstract
Introduction:Web-based cognitive tests have potential for standardized screening in
neurodegenerative disorders.Weexamined accuracy and consistency of cCOG, a com-
puterized cognitive tool, in detectingmild cognitive impairment (MCI) and dementia.
Methods:Clinical dataof306cognitivelynormal, 120mild cognitive impairment (MCI),
and 69 dementia subjects from three European cohorts were analyzed. Global cogni-
tive score was defined from standard neuropsychological tests and compared to the
corresponding estimated score from the cCOG tool containing seven subtasks. The
consistency of cCOG was assessed comparing measurements administered in clinical
settings and in the home environment.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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Results: cCOG produced accuracies (receiver operating characteristic-area under
the curve [ROC-AUC]) between 0.71 and 0.84 in detecting MCI and 0.86 and
0.94 in detecting dementia when administered at the clinic and at home. The accuracy
was comparable to the results of standard neuropsychological tests (AUC 0.69–0.77
MCI/0.91–0.92 dementia).
Discussion: cCOG provides a promising tool for detecting MCI and dementia with
potential for a cost-effective approach including home-based cognitive assessments.
KEYWORDS
Alzheimer’s disease, clinical decision support, cognition, computerized cognitive test, dementia,
memory, mild cognitive impairment, neuropsychology, web-based cognitive test
1 BACKGROUND
Despite the great progress in diagnostic biomarkers for Alzheimer’s
disease (AD) andother typesof dementia, only20%to50%ofdementia
cases are recognized and documented.1 This indicates a need for sim-
ple and efficient tools as well as clinical procedures for timely detec-
tion of neurodegenerative disorders. Although no cure for major neu-
rodegenerative disorders such as AD is available, early diagnosis, com-
bined with adequate management, can affect cognition, delay institu-
tionalization, and lead to socioeconomic benefits.2,3 Early detection
and treatment of patients with cognitive impairment is estimated to
be cost effective evenwhen taking the increased assessment costs into
account.4
In clinical practice, elderly persons with suspected cognitive
impairment are typically first evaluated with simple cognitive tests,
such as the Mini-Mental State Examination (MMSE),5 Montreal
Cognitive Assessment,6 Clock Drawing Test7 or Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD) battery.8
Further examinations with comprehensive neuropsychological assess-
ments are ordered according to the clinical symptoms and cogni-
tive screening results already obtained. Neuropsychological exami-
nations are, however, time consuming and require a specialist psy-
chologist. Web-based tests may increase the availability of testing (in
the clinic, and perhaps even at home) and help to reduce costs at
the same time.9,10 In addition, results can be more easily integrated
into electronic patient data platforms.11 Web-based cognitive tests
have been found to be promising in measuring cognition in popu-
lation level12 and in detecting mild cognitive impairment (MCI) and
dementia.13,14 However, test performance can vary depending on test
devices.12,15,16 Also retest reliability of self-administered cognitive
tests and their correlation to the traditional neuropsychological tests
varies.12,14,17
Despite the clear benefits and potential of web-based tests, they
are clearly underused in clinical settings. In this study, we present
a web-based self-administrable cognitive test tool, cCOG, designed
for early detection of neurodegenerative disorders. cCOG tasks were
developed based on traditional cognitive tests to maintain the inter-
nal validity and to support clinicians to interpret the results. In
validation, the correlation with standard neuropsychological tests
(presenting the gold standard of cognition) was studied first. Then, the
test tool accuracy to detectMCI and dementiawas evaluated and com-
pared to standard neuropsychological tests. Finally, the internal con-
sistency of the cCOG was studied with a special interest in comparing




Three study cohorts including cCOGmeasurements were used:
1) The PredictND (Predict Neurodegenerative Disorders) cohort
(PredictND) included patients withMMSE≥ 25 and contained data
from323 cognitively normal,MCI, and dementia patients from four
European memory clinics. The data were acquired during 2015 to
2016.18,19
2) The VPH-DARE@IT (Virtual Physiological Human: Dementia
Research Enabled by Information Technology) cohort (VPHDARE,
www.vph-dare.eu) containeddata from80cognitivelynormal,MCI,
and dementia patients from one memory clinic in Finland. This was
acquired during 2015 to 2016.20
3) The Finnish Geriatric Intervention Study cohort (FINGER)21 con-
tained data from 92 subjects who had an overall cognitive per-
formance at the mean level or slightly lower than expected for
their age according to Finnish population norms, did not have a
diagnosed MCI or dementia, but were at higher risk of developing
dementia. Thedatawere acquiredduring2013 to2014.All patients
providedwritten informed consent for their clinical data to be used
for research purposes. Demographic and clinical group characteris-
tics of the cohorts are summarized in Table 1.
In addition, the Amsterdam Dementia Cohort, composed of data
from memory clinic patients assessed between 2004 to 2014,22,23
was used as a separate reference data cohort for developing a
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composite cognitive score fromstandard neuropsychological tests (see
below). Data from 138 cognitively normal individuals and 470 demen-
tia patients were used.
2.2 Clinical assessment
The participants in all the cohorts received a clinical work-up includ-
ing medical history, physical assessment, traditional neuropsychologi-
cal assessments, and laboratory tests. Subjects were diagnosed as cog-
nitively normal when the cognitive complaints could not be confirmed
by cognitive testing and criteria for MCI or dementia were not met.
ThePetersen criteriawere used to defineMCI.24,25 Patientswere diag-
nosed with dementia according to the criteria for the specific underly-
ing neurodegenerative disorder.26-32
2.3 Global cognitive score based on standard
neuropsychological tests
A global cognitive score composed of several standard neuropsycho-
logical tests was developed to serve as a gold standard for the over-
all status of cognition. This score was developed to optimally separate
cognitively normal cases from cases with cognitive impairment.
To construct a global cognitive score, we selected a subset of
tests that was available in all the cohorts: MMSE5 was selected as
a measure for global cognition, learning and delayed recall scores of
Rey Auditory Verbal Learning Task (RAVLT)33 or CERAD word list
memory task for episodic memory,8 Trail Making Test A and B con-
ditions (TMT-A, TMT-B) for mental processing speed and executive
function,34 categorical (animals) verbal fluency for languageandexecu-
tive function,35 and digit span test (forward and backward)36 for work-
ing memory/attention and executive functioning. To bridge differences
between cohorts, Z-scores for RAVLT and CERADwere used.
The independent Amsterdam Dementia Cohort was used for set-
ting the parameters of the global cognitive score, which was defined
as an index computed by feeding the abovementioned measures to
the disease-state index (DSI) classifier.37 DSI is a supervised learning
method that processes heterogeneous patient data to derive a numeric
index value between zero and one denoting the disease status of a
patient. In this study, a global cognitive score value of zeromeans a high
similarity to subjects with dementia (worse cognitive performance)
while thevalueofonemeansahigh similarity to cognitivelynormal sub-
jects (better cognitive performance). Finally, a global cognitive score
was computed for all subjects of the PredictND, VPHDARE, and FIN-
GER cohorts. The supporting information appendix gives more details
about themethod.
2.4 Computerized cognitive test tool (cCOG)
In PredictND and VPHDARE, patients performed the computerized
test tool (cCOG) as part of the aim of these studies to develop com-
RESEARCH INCONTEXT
1. Systematic review: We reviewed the scientific literature
regarding the early detection of neurodegenerative dis-
orders using computerized cognitive screening tests.
2. Interpretation: Results of this study indicate that our
novel developed web-based cognitive test tool, cCOG,
is comparable to the traditional paper-and-pencil neu-
ropsychological tests in detecting mild cognitive impair-
ment (MCI) and dementia disorders. The parameters
of the new test tool had strong correlations with
traditional neuropsychological tests. In addition, con-
sistency of self-administered home assessments and
superintended assessments conducted in clinic was high,
especially for the total cCOG score.
3. Futuredirections: This article proposes that thenewweb-
based cognitive test tool is accurate in discriminatingMCI
and dementia from elderly with normal cognition. More
research is needed to confirm its properties in detecting
cognitive change over time. Future studies focusing on
the use of cCOG in a stepwise diagnostic approach could
in addition be beneficial.
puter tools for dementia diagnostics. In FINGER, cCOGwas performed
as an exploratory measure after the completion of an interventional
study, assessing the efficacy of a 2-year lifestyle intervention on cog-
nition. In all three studies, patients performed the web-based test tool,
cCOG, superintendedat baseline at the clinical sites. InPredictND, par-
ticipants were asked to repeat the test battery four times to evaluate
performance in the clinic and at home: at baseline and 12 months
superintended at the memory clinics, and 6 months and 18 months
independently at home (for which an online reminder was sent twice,
including a direct link to cCOG).
The computerized test battery is based on the three classical cog-
nitive tasks: a modification of wordlist test,8,33 simple reaction task,38
and Trail Making Test.34 It is divided into seven tasks, taking approx-
imately 20 minutes to complete. A keyboard and mouse or a touch-
screen device were used. The test battery is currently available in five
languages: English, Finnish, Danish, Dutch, and Italian.
Task 1 (Episodic memory test: learning task) is a classical memory
test in which the user is asked to remember 12 words shown one by
one. Memory encoding is supported by a simultaneously presented
visual image of the target word, that is, the word “CAR” is presented
with a picture of a car. After word/picture combinations have been
presented, the subject is asked to type as many words as she/he can
remember. The same list is shown three times, followed by the imme-
diate recalls. The order of the words varies between the rehearsal
rounds.
Tasks 2–3 (Reaction tests) measure attention and reaction speed.
Stimuli are letters shown on the screen indicating the direction (right
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TABLE 1 Characteristics of subjects (mean± standard deviation) included in the three study cohorts PredictND, VPHDARE, and FINGER, and
in the ADC reference cohort
PredictND PredictND - longitudinal
CN MCI DEM CN MCI DEM
n= 195 n= 83 n= 45 n= 94 n= 31 n= 9
Female (%) 66 37 47 66 42 33
Age (years) 64 ± 9 71 ± 7 71 ± 10 63 ± 8 70 ± 8 71 ± 12
Education (years) 14 ± 4 12 ± 4 13 ± 4 14 ± 3 13 ± 4 12 ± 5
Neuropsychology
MMSE 29.3 ± 1.0 27.9 ± 1.6 27.2 ± 1.9 29.4 ± 1.0 27.9 ± 1.6 27.6 ± 2.1
Memory, learning
b
43 ± 10 37 ± 15 25 ± 16 43 ± 11 42 ± 18 26 ± 14
Memory, recall
b
10 ± 3 6 ± 5 2 ± 4 9 ± 3 8 ± 5 3 ± 5
TMT-A (s) 37 ± 16 47 ± 17 61 ± 49 34 ± 9 41 ± 12 71 ± 72
TMT-B (s) 84 ± 46 131 ± 60 172 ± 82 73 ± 34 112 ± 55 158 ± 81
Category fluency 24 ± 7 20 ± 6 15 ± 5 25 ± 7 21 ± 6 15 ± 8
VPHDARE FINGER ADC
CN MCI DEM CN CN DEM
n= 19 n= 37 n= 24 n= 92 n= 138 n= 470
Female (%) 53 49 50 46 39 43
Age (years) 66 ± 6 70 ± 9 66 ± 8 70 ± 5 60 ± 8 66 ± 8
Education (years) 14 ± 4 11 ± 4 12 ± 4 10 ± 3 5 ± 1a 5 ± 1a
Neuropsychology
MMSE 28.8 ± 1.1 26.4 ± 2.4 23.9 ± 4.8 27.9 ± 1.9 28.4 ± 1.5 21.9 ± 4.8
Memory, learning
b
42 ± 10 35 ± 13 24 ± 14 42 ± 12 44 ± 10 24 ± 10
Memory, recall
b
9 ± 3 7 ± 4 4 ± 4 8 ± 4 10 ± 3 3 ± 3
TMT-A [s] 37 ± 16 51 ± 26 68 ± 29 37 ± 16 37 ± 16 88 ± 64
TMT-B [s] 84 ± 46 111 ± 53 144 ± 45 84 ± 46 84 ± 46 220 ± 112
Category fluency 23 ± 5 20 ± 6 15 ± 6 22 ± 6 23 ± 6 12 ± 6
“PredictND – longitudinal” is a subcohort for which cCOGwasmeasured in all four time points.
Abbreviations: cCOG, computerized cognitive test;CERAD,ConsortiumtoEstablish aRegistry forAlzheimer’sDisease;CN, cognitively normal;DEM,demen-
tia; MCI, mild cognitive impairment;MMSE,Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test.
aVerhage rating scale for education
bConverted fromCERAD scores to RAVLT scores using z-score comparison
and left) to which the user should react by pressing the arrow button
as quickly as possible. In Task 2, the user should hit the arrow button
on the right “→” whenever “R” is displayed. In Task 3, both “R” and “L”
letters are displayed, and the user should hit the right arrow “→” for “R”
and the left arrow “←” for “L.”
Tasks 4–5 (modified Trail Making Tests) measure visuomotor speed,
attention, and executive function. In Task 4, the user is asked to select
the numbers from 1 to 24 in the ascending order as quickly as possi-
ble. Numbers from1 to 24 located on the squares are shown in random
locations on the screen. In Task5, the usermust again click the numbers
inorder; however, this timeeachnumber from1 to24 is presentedboth
in the circle and square. Altogether 48 stimuli are shown on the screen
and the user is asked to select numbers in ascending order but every
first time a circle and every second a square in a sequence (one inside
circle, two inside square, three inside circle, etc.).
In Task 6 (Episodic memory test: Recall task), the user is asked to
recall and type the words from Task 1.
In Task 7 (Episodicmemory test; Recognition task), the user is asked
to recognize the word/picture combinations shown previously in Task
1. The user is shown altogether 24 word/picture images and asked to
recognize whether the wordwas shown in Task 1.
cCOG tasks were quantified as follows:
Task 1: the total number of correct words recalled in immediate
trails,
Task 2 & 3: the average reaction time calculated for correct clicks,
Task 4 & 5: the duration for selecting numbers in ascending order
from 1 to 24,
Task 6: the number of correct words in delayed recall, and
Task 7: the duration of time from the beginning until the end of the
recognition task.
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Thereafter, a linear regression model was developed using Pre-
dictND data, for estimating the global cognitive score (dependent vari-
able) from the abovementioned seven features. This estimated score,
cCOG score, was then computed for all subjects of the PredictND,
VPHDARE, and FINGER cohorts. Finally,MMSE, global cognitive score,
and cCOG scores were normalized for age, sex, and education years.
2.5 Data analysis
The Spearman correlation coefficient was computed between the cog-
nitive features of cCOG and different clinical cognitive test results, for
PredictND, VPHDARE, and FINGER data. The correlations are rated as
follows: 0–0.39weak, 0.40–0.59moderate, and 0.60–1.0 strong.39
Theaccuracyof the global scores (MMSE, global cognitive score, and
cCOG) and cCOG individual subtasks in classifyingpatients todifferent
diagnostic groups was studied. Two classifiers were developed: one for
detecting MCI patients and one for detecting dementia patients. First,
the PredictND data were divided randomly into training set (75% of
cases) and test set (25% of cases). Then, the median value of the score
(MMSE, global cognitive score, and cCOG)was computed for bothdiag-
nostics groups in the training set, and the cut-off value was chosen as
the midpoint between the median values. Finally, the test set was clas-
sified using the cut-off value. A set of statistical performancemeasures
was computed: area-under-the-curve (AUC), sensitivity, specificity, and
balanced accuracy (BACC, defined as the average of sensitivity and
specificity). The whole process was repeated 1000 times and the aver-
age accuracy was calculated. In addition to cross-validation using the
PredictND data, classification performance was evaluated using the
independent VPHDARE cohort. Because the FINGER cohort does not
contain MCI and dementia patients, these data were not used for this
part of the study.
Finally, consistency of cCOG measurements at clinics and at home
in PredictND was studied by calculating the Pearson correlation coef-
ficient between different time points and by comparing classification
performance from four time points.
The Matlab toolbox R2017a (The MathWorks Inc., Natick, Mas-
sachusetts, USA) was used to run all data analyses.
3 RESULTS
3.1 Correlation with standard neuropsychological
tests
Table 2 presents the correlation coefficients ofMMSE, global cognitive
score, cCOG, and the individual cCOG tasks, with results from stan-
dard neuropsychological tests. The correlation coefficients between
global cognitive score and cCOG for PredictND, VPHDARE, and FIN-
GERcohortswere0.78, 0.81, and0.63, respectively.When correlations
between individual tasks and single cognitive tests were studied, the
highest correlations were found between episodic memory learning
(Task 1) and RAVLT/CERAD learning, r = 0.44–0.64, episodic memory
recall (Task 6) and RAVLT/CERAD recall, r = 0.47–0.54, and modified
trail making (B) (Task 5) and TMT-B, r= 0.62–0.80.
Correlation coefficients between the global scores and age were
–0.15 for MMSE, –0.16 for global cognitive score, and –0.26 for
cCOG, and between the composite scores and education years 0.09 for
MMSE, 0.12 for global cognitive score, and 0.17 for cCOG.
3.2 Classification accuracy in diagnostics
Figure 1 shows the distributions of MMSE, global cognitive score, and
cCOG for different diagnostic groups in all three study cohorts. Table 3
presents classification performance in detecting MCI and dementia
patients using MMSE, global cognitive score, and cCOG in PredictND.
The results indicate that classification accuracy is comparable between
global cognitive score and cCOG. Table A.1 in the supporting informa-
tion appendix shows classification performance also for the individ-
ual cCOG tasks. The highest values can be observed for the memory
tasks (learning and recall) both in detecting MCI and dementia while
the reaction time tasks have clearly the lowest values.
The cut-off values defined from the PredictND data were
28.3 (MMSE), 0.60 (global cognitive score), and 0.60 (cCOG) for
detecting MCI patients, and 28.2 (MMSE), 0.49 (global cognitive
score), and 0.52 (cCOG) for detecting dementia patients. When these
cutoffs were applied to the VPHDARE data, the following balanced
accuracies were obtained: 0.63 (MMSE), 0.71 (global cognitive score),
and 0.67 (cCOG) in detecting MCI patients, and 0.71 (MMSE), 0.79
(global cognitive score), and 0.78 (cCOG) in detecting dementia
patients.
3.3 Consistency of cCOG at clinic and at home
Consistency of the cCOG results between clinic and home-based
assessments was analyzed using the PredictND data. Of the 323 par-
ticipants, 25 participants performed cCOG only at baseline, 94 par-
ticipants performed cCOG twice, and 69 patients performed cCOG
three times. Only 134 participants (94 cognitively normal, 31MCI, and
9 dementia) performed cCOG at all four time points. Of these time
points, baseline and 12-month visits were administered superintended
at memory clinics, and 6- and 18-month visits at home using partici-
pants’ own computers. Assistance (mostly in typing) was reported in
21% of cases over all testing sessions; 31% of testing sessions at the
first clinical visit, and 17% of testing session after the first visit (both
at home and at the clinic). Furthermore, 79% of testing sessions were
done using touchscreen in the clinic versus only 14% at home.
Figure 2 presents the distribution of cCOG results for the differ-
ent diagnostic groups at the measurement points. AUC values were
0.79 (month 0), 0.72 (month 6), 0.76 (month 12), 0.76 (month 18)
in detecting MCI patients, and 0.94 (month 0), 0.93 (month 6), 0.91
(month 12), and 0.87 (month 18) in detecting dementia showing a
decent consistency between the clinic and home measurements. By
comparison, AUC was 0.69 in detecting MCI and 0.91 in detecting
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MMSE PDN – 0.61 0.42 0.46 0.40 −0.31 −0.40 0.22 0.19
VPH – 0.82 0.67 0.58 0.61 −0.49 −0.64 0.41 0.55
FNG – 0.56 0.26 0.28 0.35 −0.07 −0.37 0.18 0.20
Global cognitive PDN 0.61 – 0.79 0.78 0.70 −0.61 −0.73 0.39 0.51
score VPH 0.82 – 0.86 0.77 0.85 −0.74 −0.85 0.47 0.67
FNG 0.56 – 0.68 0.67 0.65 −0.52 −0.71 0.46 0.56
cCOG PDN 0.54 0.78 0.51 0.50 0.59 −0.61 −0.71 0.27 0.36
VPH 0.68 0.81 0.64 0.51 0.64 −0.65 −0.78 0.38 0.45
FNG 0.17 0.63 0.39 0.46 0.50 −0.37 −0.53 0.38 0.32
Task 1: Episodic
memory learning
PDN 0.52 0.71 0.52 0.50 0.55 −0.47 −0.58 0.21 0.30
VPH 0.56 0.67 0.64 0.53 0.55 −0.52 −0.57 0.25 0.34
FNG 0.12 0.54 0.44 0.49 0.39 −0.20 −0.40 0.46 0.31
Task 2: Simple reaction PDN −0.34 −0.36 −0.23 −0.22 −0.40 0.30 0.33 −0.05 −0.08
VPH −0.48 −0.62 −0.52 −0.42 −0.60 0.44 0.63 −0.38 −0.45
FNG −0.01 −0.42 −0.24 −0.37 −0.26 0.25 0.30 −0.19 −0.16
Task 3: Choice reaction PDN −0.29 −0.42 −0.33 −0.29 −0.37 0.33 0.36 −0.12 −0.20
VPH −0.43 −0.56 −0.39 −0.26 −0.54 0.47 0.57 −0.34 −0.45
FNG −0.11 −0.11 −0.01 −0.13 −0.11 0.14 0.16 0.13 0.13
Task 4:Modified Trail
Making (A)
PDN −0.27 −0.49 −0.17 −0.18 −0.35 0.60 0.57 −0.24 −0.31
VPH −0.44 −0.58 −0.38 −0.30 −0.46 0.55 0.66 −0.44 −0.49
FNG −0.28 −0.55 −0.31 −0.28 −0.39 0.31 0.55 −0.31 −0.31
Task 5:Modified Trail
Making (B)
PDN −0.32 −.60 −0.30 −0.29 −0.42 0.65 0.70 −0.28 −0.37
VPH −0.65 −0.74 −0.51 −0.43 −0.57 0.58 0.80 −0.41 −0.51
FNG −0.20 −0.58 −0.25 −0.28 −0.46 0.44 0.62 −0.21 −0.28
Task 6: Episodic
memory recall
PDN 0.48 0.66 0.49 0.54 0.49 −0.42 −0.50 0.17 0.26
VPH 0.53 0.59 0.52 0.53 0.48 −0.43 −0.51 0.27 0.22
FNG 0.08 0.47 0.38 0.47 0.35 −0.21 −0.31 0.29 0.23
Task 7: Episodic
memory recognition
PDN −0.40 −0.60 −0.35 −0.35 −0.43 0.52 0.59 −0.23 −0.28
VPH −0.67 −0.75 −0.55 −0.45 −0.60 0.63 0.75 −0.38 −0.49
FNG −0.15 −0.39 −0.12 −0.19 −0.42 0.30 0.40 −0.32 −0.26
Abbreviations: cCOG, computerized cognitive test;CERAD,ConsortiumtoEstablish aRegistry forAlzheimer’sDisease;CN, cognitively normal;DEM,demen-
tia; MCI, mild cognitive impairment;MMSE,Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test.
Notes: Color scaling dependent on absolute values of correlation: no color for very weak or weak correlation (0–0.39), light red for moderate correlation
(0.40–0.59), red for strong or very strong correlation (0.60–1.00).
dementia when using the global score from standard neuropsychologi-
cal tests at the baseline.
Table 4 presents the Pearson correlation coefficient for test-retest
consistency between the two cCOG measurements either at clinic, at
home, or between clinic and home.
4 DISCUSSION
This study validated a self-administrable web-based cognitive test
tool for the early detection of neurodegenerative disorders. The
test was designed in such a way that tasks resemble standard
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F IGURE 1 Distributions ofMini-Mental State Examination, global cognitive score, and computerized cognitive tool (cCOG) global score shown
for different diagnostic groups of the PredictND cohort (blue), VPHDARE cohort (orange), and FINGER cohort (gray) using boxplots. For each
boxplot, the line and cross indicate themedian andmean values, respectively, and the bottom and top edges of the box indicate the 25th and 75th
percentiles, respectively. The whiskers extend to themost extreme data points not considered outliers, and the outliers are plotted individually
TABLE 3 Classification performance in the PredictND cohort (mean; 95% confidence interval)






AUC 0.75 (0.63 0.86) 0.77 (0.66 0.88) 0.84 (0.75 0.92) 0.84 (0.71 0.94) 0.91 (0.77 0.99) 0.92 (0.83 0.98)
BACC 0.68 (0.58 0.78) 0.71 (0.61 0.80) 0.77 (0.67 0.86) 0.78 (0.66 0.89) 0.88 (0.76 0.96) 0.83 (0.71 0.93)
Sensitivity 0.66 (0.45 0.85) 0.71 (0.50 0.90) 0.77(0.57 0.95) 0.72 (0.45 0.92) 0.86 (0.64 1.00) 0.75 (0.50 1.00)
Specificity 0.71 (0.57 0.84) 0.71 (0.58 0.84) 0.77 (0.67 0.88) 0.83 (0.71 0.94) 0.89 (0.81 0.96) 0.91 (0.83 0.98)
Abbreviations: AUC, area under the curve; BACC; balanced accuracy; cCOG, computerized cognitive test; CN, cognitively normal; DEM, dementia;MCI, mild
cognitive impairment;MMSE,Mini-Mental State Examination.
neuropsychological tests making interpretation easier for clinicians.
Classification accuracy was high in detecting both patients with MCI
and dementia, and comparable to the global cognitive score derived
from standard neuropsychological tests. Furthermore, accuracy was
relatively consistent over time andbetween testing at homeor in clinic.
A recent systematic review reported accuracies for 11 comput-
erized tools in detecting either MCI or early dementia based on 14
studies.40 The performance was reported either for the overall output
of the tool, for the subtasks of the tool, or both. The median value of
AUC was 0.85 and the balanced accuracy was 0.77 in detecting MCI.
The corresponding values in detecting early dementia were 0.82 for
AUC and 0.85 for balanced accuracy. These results are comparable to
the performance reported in this work. The time needed for testing is
also an important factor when considering feasibility. The time used in
testing for those 11 tools varied between 10 and 45 minutes, which is
comparable to about 20minutes used for cCOG.Despite this review, to
date, very few automated computerized tools are being used in clinical
practice.Our study adds to thiswork by developing aweb-based cogni-
tive test tool that uses tests that are easy to interpret and use in clinical
practice. Furthermore, the developed test showed consistent perfor-
mance when used at home or in clinic. In addition, computerized test-
batteries can be beneficial in emergency situations (such as the current
COVID-19 pandemic) for which remote assessments are needed.
Several factors can affect test accuracy. First, it is well known that
diagnostic accuracy improves at later stages of neurodegenerative dis-
eases. MMSE scores 20 to 24 are considered to suggest mild demen-
tia. In PredictND, the average MMSE score for dementia patients was
27.2, indicating that these patients received their diagnosis at a very
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TABLE 4 Pearson correlation coefficients between different time points for the cCOG tasks and the global score at clinic, at home, and



























0.75 0.48 0.42 0.69 0.69 0.72 0.64 0.82
Home (N= 134)
M6-M18
0.69 0.48 0.54 0.63 0.44 0.59 0.78 0.77
Clinic-Home
(N= 186)M0-M6
0.54 0.42 0.24 0.63 0.63 0.57 0.59 0.67
Clinic-Home
(N= 177)M6-M12




0.69 0.34 0.48 0.64 0.61 0.65 0.66 0.74
Abbreviations: cCOG, computerized cognitive test;M0, baseline visit atmemory clinic;M12, 12months visit atmemory clinic;M18, 18months visit at home;
M6, 6months visit at home.
F IGURE 2 Computerized cognitive tool (cCOG) retest
distributions in follow-up setting. Distributions of cCOG for the
cognitively normal (CN), mild cognitive impairment (MCI), and
dementia (DEM) groups at baseline (first dark blue, clinic), month 6
(first light blue, home), month 12 (second dark blue, clinic), andmonth
18 (second light blue, home). The distributions have been computed
only from the subjects having all four time points available (n= 136)
early phase. The cCOGassessmentwasperformed inPredictNDonly in
memory clinic patients with MMSE ≥ 25 explaining the normal MMSE
value. The accuracy obtained in this cohort is thus fairly high despite
the fact that these patients were all very mild dementia cases, in which
diagnosis ismore challenging. Interestingly, the cognitively normal sub-
jects at risk inFINGERhad the sameaverageMMSEscore (27.9) asMCI
patients in PredictND. These results demonstrate possible differences
in clinical populations but potentially also how diagnostic criteria are
applied. Second, the number of subjects in the VPHDARE cohort was
relatively lowwith only 19 cognitively normal subjects. Thismeans that
the impact of a single subject on accuracy is considerable and random
effectsmay explain differences. Because of these reasons, the accuracy
values reported should be considered only indicative.
cCOG had high correlations with the global cognitive score from
standard neuropsychological tests in the three cohorts studied,
r = 0.63–0.81. When correlations between individual cCOG tasks
and single cognitive tests were studied, the highest correlations were
found for the memory domain and executive functioning domain. For
comparison, Mielke et al.12 reported correlations of the CogState
computerized tests and standard neuropsychological tests in a non-
demented elderly cohort including both cognitively normal and MCI
subjects. The correlations were r = 0.13–0.34 for delayed recall and
r = 0.24–0.47 for TMT-B. In some studies correlations between the
computerized tests and paper-and-pencil tests have been very weak
(r = 0.09–0.26 for immediate recall, r = 0.09–0.23 for delayed recall,
and r=0.02–0.28 forTMT-B),41 but inother studies computerized cog-
nitive batteries have yielded moderate to high correlation (r = 0.47–
0.71) with traditional tests also in the healthy population.14 In gen-
eral, correlations between cCOG and traditional neuropsychological
tests were good when compared to previously developed web-based
test batteries.12,16,42,43 Also cCOGmemory subscore correlationswith
traditional memory tests were comparable to those reported recently
amongMCI and healthy elderly.17
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The consistency over time was studied using data from four time
points, two measured at clinic and two at home. cCOG showed very
strong correlation both in clinic (r = 0.82) and at home (r = 0.77).
For comparison, Hammers et al.44 studied test-retest reliability using
the CogState test battery and reported correlations for different tasks
between r= 0.23–0.79 in healthy controls, 0.33–0.75 in MCI subjects,
and 0.59–0.80 in AD. Cacciamani et al.45 reported test-retest reliabil-
ity for the CANTAB (Cambridge Neuropsychological Test Automated
Battey) test in MCI subjects over three time points. The Paired Asso-
ciates Learning test (total errors) provided the highest correlation over
three measurements, r = 0.74–0.85. The same test gave correlation
r = 0.68 in an older elderly cohort without neuropsychiatric diagno-
sis in Goncalves et al.46 They reported the highest test-retest per-
formance for a reaction time test (RTI five-choice movement time),
r = 0.86, while the reaction times tests produced variable results in,45
r = 0.03–0.82. In cCOG, correlations for the reaction time tests were
only r= 0.42–0.54. In Maljkovic et al.,47 CANTAB was administered at
home and the highest test-retest correlation in a healthy control, MCI,
and dementia cohort was obtained for memory tests, intraclass corre-
lation> 0.71.
In our study, a single composite score was developed both for the
standard neuropsychological tests and for the cCOG test tool. Recent
research implies that composite scores of memory and global cogni-
tion can be more sensitive than single test scores in detecting cog-
nitive impairment in prodromal AD,48,49 supporting this approach. In
addition, a single index score is easier to interpret in screening pur-
poses than a battery including several separate scores. Finally, auto-
matic adjustment of demographic variables is also straightforward in
the computerized tests.
Regarding the feasibility of cCOG, assistance was requested in 21%
of testing sessions. In most cases, assistance was needed in typing. To
alleviate this challenge and improve usability, we have updated cCOG
so that the user needs to type only the first three letters and if they are
right, theword is completed automatically. Voice recognition could also
be an option for future versions.
The main strength of this study was the use of three different
cohorts in validation and comparison to standard neuropsychologi-
cal tests. The main limitation, however, was a relatively limited sam-
ple size. Less than half of the PredictND subjects did cCOG at all
four time points. Another limitation was that our study design was
not optimal for defining test-retest reliability. Instead of having two
measurements made within a short period of time, the time differ-
ence was 6 or even 12 months. Yet, this can also be considered an
advantage, preventing learning effects. In addition, testing at home
was not controlled in any way as patients used their own comput-
ers. Only 14% of testing sessions were done using a touchscreen at
home while the number was 79% at clinics. Although no big differ-
ence was observed between the clinic and home measurements, stan-
dardizing the hardware would potentially improve reproducibility. A
systematic study about the impact of the hardware should be per-
formed in the future. Finally, our study on the role of individual tasks
remained limited. Because the number of dementia cases was rela-
tively small, we could not evaluate how the tasks reflecting different
domains of cognition performance in separating different dementia
etiologies.
In conclusion, the web-based cCOG test tool demonstrated cor-
responding accuracy in detecting MCI and dementia with a compos-
ite score derived from standard neuropsychological tests. In addi-
tion, cCOGresults showed high consistencywhenmeasurementswere
administered at home and in the clinic. These results give support that
cCOG could be a useful and cost-efficient tool in early assessment for
neurodegenerative diseases. Tools like this can even be administered
at home and can pave the way for stepwise approach diagnostics in
dementia.
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